Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Operating Expenses: 2019-2025

Historic Operating Expenses for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $95.3 million.

  • Kymera Therapeutics' Operating Expenses rose 25.60% to $95.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.0 million, marking a year-over-year increase of 30.66%. This contributed to the annual value of $308.7 million for FY2024, which is 26.46% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Operating Expenses stood at $95.3 million, which was down 0.78% from $96.0 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Operating Expenses ranged from a high of $96.5 million in Q1 2025 and a low of $31.9 million during Q1 2021.
  • In the last 3 years, Kymera Therapeutics' Operating Expenses had a median value of $75.9 million in 2024 and averaged $76.4 million.
  • Data for Kymera Therapeutics' Operating Expenses shows a peak YoY surged of 147.42% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Kymera Therapeutics' Operating Expenses stood at $49.3 million in 2021, then grew by 11.16% to $54.8 million in 2022, then rose by 22.69% to $67.2 million in 2023, then soared by 31.18% to $88.1 million in 2024, then rose by 25.60% to $95.3 million in 2025.
  • Its last three reported values are $95.3 million in Q3 2025, $96.0 million for Q2 2025, and $96.5 million during Q1 2025.